Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-241-0
CAS number: -
Table 1. Mean parameters ( ±SD)
of hematology and serum chemistry that had significant differences
between exposed and control groups following subchronic exposures.
480 ppm DIPE
3300 ppm DIPE
7100 ppm DIPE
0.61 ± 0.06
0.64 ± 0.04
0.67 ± 0.06
0.69 ± 0.03b
71 ± 10
74 ± 13
77 ± 17
77 ± 9
95 ± 22d
11 ± 5
16 ± 7
13 ± 6
9 ± 3c
92 ± 3
92 ± 4
90 ± 6
90 ± 4
87 ± 6b
1 ± 2
2 ± 2
3 ± 2b
4.96 ± 0.35
4.68 ± 0.24
4.58 ± 0.41
4.51 ± 0.37b
4.45 ± 0.40b
88 ± 5
86 ± 6b
85 ± 7b
86 ± 3b
apercent of total white blood cells.
bSignificantly different from untreated controls.
cSignificantly different from sham-exposed controls.
dSignificantly different from both control groups.
Read across from diisopropylether (DIPE) is justified on the basis that
NOAECs reported for the constituents of this UVCB range from 3500 mg/m3
for hexanol to 31680 mg/m3 for propylene dimers, which
can be considered indicative of low toxicity for this UVCB substance.
DIPE comprises approximately 50% of the UVCB substance and is,
therefore, the main constituent. The C6 alkanes/alkenes are, with 20%,
the second largest constituent. The NOAECs of both DIPE and C6
alkanes/alkenes, together accounting for approximately 70% of the UVCB
substance, are in the same order of magnitude (3300 ppm and 3000 ppm,
Mild hypertrophy was observed at the high-dose in combination with 39%
(male) and 18% (female) increased absolute liver weight. The high dose
of 7100 ppm was considered to be the LOAEC effect level.
At the mid-dose, no histopathological changes were observed. Absolute
liver weight gain was 26% in males only; 6% in females. Sorbitol
dehydrogenase dropped from 11(5) or 16(7) IU/L in controls to 9(3) IU/L.
The absolute liver weight gain seen only in males, and unaccompanied by
other effects, is considered to be a suitable NOAEC.
Based on "adverse liver effects" criteria by TERA (Toxicology Excellence
for Risk Assessment): presence of histopathology (moderate hypertrophy)
in combination with statistically significant absolute or relative
weight changes; or liver weight change >10%; or doubling of serum levels
of liver enzyme activity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again